ranibizumab (Lucentis)

Following a full  resubmission:

ranibizumab (Lucentis®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of visual impairment due to diabetic macular oedema (DMO) in adults.

SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline. 

Ranibizumab significantly improved visual acuity over 12 months compared with standard laser photocoagulation treatment. Open label extension results up to 3 years suggest maintenance of effect.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ranibizumab. This SMC advice is contingent upon the continuing availability of the patient access scheme or a list price that is equivalent or lower.